Anti-Counterfeit Drugs
Pharmaceutical anti-counterfeiting is governed by mandatory regulated systems: unit-level serialization and track-and-trace under the US DSCSA and EU FMD, using 2D Data Matrix codes, tamper-evident packaging, and verification against systems like the EMVS before dispensing. Nothing replaces them. Separately, the batch documents that travel with medicines — Certificates of Analysis, batch-release certificates — can be made verifiable so recipients confirm they were genuinely issued and unaltered. That document-integrity layer complements serialization; it is not a substitute for it.
Pharmaceutical anti-counterfeiting is governed by mandatory, regulated systems: unit-level serialization and track-and-trace under the US DSCSA and the EU Falsified Medicines Directive, using 2D Data Matrix codes, tamper-evident packaging, and verification against systems like the EMVS before a medicine is dispensed. These are the primary, legally required defence, and nothing replaces them. Separately — and as a complement, not a substitute — the batch documents that travel with medicines, such as Certificates of Analysis and batch-release certificates, can be made verifiable so recipients can confirm they were genuinely issued and haven't been altered. This guide explains both layers, and exactly where each fits.
The crucial distinction: serialization under DSCSA and FMD protects and traces the units, and is mandatory. Verifiable batch documentation protects the certificates that accompany a batch. They are different layers, and neither replaces the other. This is general information only — not regulatory, compliance, legal, or medical advice; compliance with DSCSA, FMD, and other mandates must be met through the regulated systems they require.
Falsified and counterfeit medicines are a serious public-health threat: they can be substandard, contaminated, or contain the wrong active ingredient, with direct consequences for patients. That's why pharmaceuticals are the most heavily regulated domain in anti-counterfeiting, with legally mandated systems in dozens of markets.
The core defence is unit-level serialization plus track-and-trace, mandated by law.
The Drug Supply Chain Security Act, or DSCSA, enacted in 2013, requires each package to carry a unique product identifier — a GTIN, serial number, lot number, and expiry date — encoded in a 2D Data Matrix and human-readable form. After several delays, the FDA moved to active enforcement in 2025: trading partners must exchange serialized transaction data electronically, typically via EPCIS, and verify that the 2D Data Matrix matches the electronic data, with interoperable systems across manufacturers, wholesalers, and dispensers. Non-compliance can bring fines, licence action, and criminal penalties.
Under the Falsified Medicines Directive, or FMD, since 9 February 2019 most prescription medicines must carry two safety features: a unique identifier in a 2D Data Matrix and an anti-tampering device on the outer packaging. Distributors and pharmacies authenticate each pack against the European Medicines Verification System, the EMVS, and decommission it at the point of dispensing.
More than 78 countries now mandate serialization, largely built on GS1 standards. This regulated infrastructure is the primary, mandatory defence — and verifiable document tools do not replace it.
It's worth being honest about a limitation the industry itself acknowledges. A serialized 2D Data Matrix is, ultimately, a replicable label: a copied legitimate code can be applied to counterfeit packaging and may still pass verification depending on scan timing and workflow. Serialization frameworks were built primarily for traceability, not adversary-resistant security, and operational seams — returns, permissive re-scans, unanalysed serial-event data — can be exploited without breaking serialization. The lesson is that robust protection is layered, and that the integrity of records and documents around a batch matters alongside the codes on the packs.
A pharmaceutical batch doesn't travel alone — it travels with documents. A Certificate of Analysis attests to a batch's test results; a batch-release certificate, Certificate of Conformity, GMP certificate, or Certificate of a Pharmaceutical Product support its movement through the supply chain. These documents are heavily relied upon — especially in API and excipient sourcing, cross-border trade, and business-to-business hand-offs — and forged or altered batch certificates are a genuine supply-chain problem. Yet such documents are often passed around as PDFs or scans with no independent way to confirm they were genuinely issued by the manufacturer and not altered.
This is the gap that verifiable issuance addresses. A batch document can be issued with a built-in way to verify it at source — a QR code linking to a proof page that confirms the document genuinely came from the manufacturer and hasn't been changed. A wholesaler, importer, hospital pharmacy, or regulator can then confirm a Certificate of Analysis or batch-release document in seconds, rather than trusting a forwarded file. This is a document-integrity layer that complements serialization; it concerns the authenticity of the paperwork, not unit-level track-and-trace.
VerifyDoc.ai makes batch documents verifiable: a manufacturer can issue a Certificate of Analysis, batch-release, conformity, or GMP document carrying a QR-backed verification layer and proof page, so any recipient can confirm at source that the document is genuine and unaltered.
It's essential to be precise about scope. VerifyDoc.ai is not a DSCSA, FMD, or EMVS serialization or track-and-trace system, and not a compliance solution for those mandates — those obligations must be met through the regulated systems, such as EPCIS data exchange and EMVS verification. VerifyDoc.ai does not serialize or verify physical drug units, does not authenticate the physical pack, does not detect counterfeit medicines, and is not a substitute for tamper-evident packaging, unit-level serialization, or pharmacovigilance. Its role is strictly the verifiable-document layer — making the batch certificates and supply-chain documents you issue confirmable at source — alongside, never instead of, the mandatory regulated systems. See how it works.
VerifyDoc.ai lets manufacturers issue Certificates of Analysis and other batch documents with a built-in verification layer — so partners and regulators can confirm at source that the paperwork is genuine and unaltered. It complements, and does not replace, regulated serialization. Start free or see how it works.
Related reading: Anti-counterfeit: QR Certificates of Authenticity for consumer brands, What actually proves a document is authentic?, and How to issue a Certificate of Authenticity.
This article is for general information and does not constitute regulatory, compliance, legal, or medical advice. Pharmaceutical anti-counterfeiting and traceability are governed by mandatory regulations such as the DSCSA and FMD, which must be complied with through the systems they require.
Primarily through mandatory unit-level serialization and track-and-trace under regulations like the US DSCSA and EU FMD — unique 2D Data Matrix codes, tamper-evident packaging, and verification against systems such as the EMVS before dispensing. Verifiable batch documentation can add a complementary document-integrity layer.
Serialization (DSCSA/FMD) identifies and traces individual medicine packs and is legally required. Verifiable batch documentation confirms that the certificates accompanying a batch, like a Certificate of Analysis, are genuinely issued and unaltered. They are separate, complementary layers.
Yes — a serialized 2D Data Matrix is a replicable label, and a copied legitimate code can sometimes pass verification depending on workflow. That's why the industry treats serialization as part of a layered defence rather than a complete solution.
No. DSCSA and FMD compliance must be achieved through the regulated serialization and verification systems they mandate. VerifyDoc.ai only makes batch documents verifiable and does not provide serialization, track-and-trace, or unit-level compliance.
No. VerifyDoc.ai verifies documents, not physical drug units. It cannot authenticate a physical pack or detect a counterfeit medicine — that role belongs to regulated serialization, tamper-evident packaging, and supply-chain verification systems.
